Nebulized Furosemide for Pulmonary Inflammation in Intubated Patients With COVID-19: A Phase 2 Randomized Controlled Double-Blind Study

Nebulized Furosemide for Pulmonary Inflammation in Intubated Patients With COVID-19: A Phase 2 Randomized Controlled Double-Blind Study

OBJECTIVES:. Respiratory failure secondary to COVID-19 is associated with morbidity and mortality. Current anti-inflammatory therapies are effective but are given systemically and have significant side effects. Furosemide has anti-inflammatory properties, can be administered by inhalation, and is in...

Full description

Bibliographic Details
Main Authors: John Muscedere, MD, David M. Maslove, MD, MS, Christopher J. Barden, PhD, Donald F. Weaver, MD, PhD, J. Gordon Boyd, MD, PhD, Stephanie Sibley, MD, MS, Tracy Boyd, Oleksa Rewa, MD, MSc, Martin Albert, Marios Roussos, MD, MPH, Patrick A. Norman, MSc, Andrew G. Day, MSc, for the Canadian Critical Care Trials Group
Format: Article
Language:English
Published: Wolters Kluwer 2024-02-01
Series:Critical Care Explorations
Online Access:http://journals.lww.com/10.1097/CCE.0000000000001045

Internet

http://journals.lww.com/10.1097/CCE.0000000000001045

Similar Items